Victor J Hruby
Regents Professor Emeritus
Our research is centered on the prevention and treatment of our major degenerative diseases. We concentrate on peptide hormones and neurotransmitters and their receptors that are involved in these major diseases. Specific potential applications include pigmentary disorders, melanoma cancer, feeding disorders, pain, sexual function and motivation, and neurodegenerative diseases such as Alzheimer's, Parkinson's, etc.
Victor J. Hruby, PhD, M.S., B.S. is a Regents Professor of Chemistry and Biochemistry in the College of Science at the University of Arizona where he has been a Professor for 44 years. He has a Joint appointment in the Neuroscience program and the Department of Medical Pharmacology and in several other programs at the University of Arizona. Dr. Hruby is world renowned as one of the top scientists in the world in peptide chemistry and biology, especially peptide hormones and neurotransmitters that are critical to all biological behaviors and are involved in most of our major degenerative diseases. He and his students and colleagues have developed most of the major scientific strategies used in the design, synthesis and conformational analysis, structure-activity relationships and chemical biology, pharmacology and physiology of ligands for G-Protein Coupled Receptors (GPCRs) that are the target for about 50% of our current drugs. He collaborates extensively with biophysicists, biologists and medical doctors in his research. He has published over 1100 papers, book chapters, reviews, etc. and has co-edited two books and co-written one book. He has won many major awards nationally and internationally and is a plenary or featured speaker at numerous national and international conferences every year. Recently, for example, he was the recipient of the Cope Award of the American Chemical Society, the Meienhofer Award in Peptide and Protein Science sponsored by the Roche Company, was elected to the ACS Medicinal Chemistry Hall of Fame, and was Arizona Innovator of the Year.With colleagues in the College of Science and the College of Medicine, he has put several drugs into clinical trials for pigmentation without sun, for cancer prevention and protection from the damage of UV radiation, and for erectile dysfunction. Currently, he and his colleagues are developing novel multivalent ligands for the treatment of the most ubiquitous disease in the U.S. and worldwide, prolonged and neuropathic pain without the toxicities of current pain medications and the development of tolerance, and for the detection and treatment of cancer among other medical needs. Keywords: chemical biology, hormones and neurotransmitters, degenerative diseases, disease prevention